Conclusions
In conclusion, tofacitinib is more effective than placebo in the treatment of MTA-resistant RA up to 24 weeks. Tofacitinib is well tolerated as no statistically significant AEs impacting the immune or hematologic system were observed in short-term studies compared with placebo. Despite significantly lower neutrophil counts in tofacitinib group, there were no associated treatment withdrawals. However, further studies on long-term efficacy and pharmacovigilance studies are still needed to support long-term use.